|
1
|
Lu H, Ouyang W and Huang C: Inflammation,
a key event in cancer development. Mol Cancer Res. 4:221–233. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vogelstein B and Kinzler KW: Cancer genes
and the pathways they control. Nat Med. 10:789–799. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Macaluso M, Paggi MG and Giordano A:
Genetic and epigenetic alterations as hallmarks of the intricate
road to cancer. Oncogene. 22:6472–6478. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Swann JB and Smyth MJ: Immune surveillance
of tumors. J Clin Invest. 117:1137–1146. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ghiringhelli F, Apetoh L, Housseau F,
Kroemer G and Zitvogel L: Links between innate and cognate tumor
immunity. Curr Opin Immunol. 19:224–231. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xu D, Gu P, Pan PY, Li Q, Sato AI and Chen
SH: NK and CD8+ T cell-mediated eradication of poorly
immunogenic B16–F10 melanoma by the combined action of IL-12 gene
therapy and 4–1BB costimulation. Int J Cancer. 109:499–506. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Higuchi DA, Cahan P, Gao J, Ferris ST,
Poursine-Laurent J, Graubert TA and Yokoyama WM: Structural
variation of the mouse natural killer gene complex. Genes Immun.
11:637–648. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shankaran V, Ikeda H, Bruce AT, White JM,
Swanson PE, Old LJ and Schreiber RD: IFNgamma and lymphocytes
prevent primary tumour development and shape tumour immunogenicity.
Nature. 410:1107–1111. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yokoyama WM, Ryan JC, Hunter JJ, Smith HR,
Stark M and Seaman WE: cDNA cloning of mouse NKR-P1 and genetic
linkage with LY-49. Identification of a natural killer cell gene
complex on mouse chromosome 6. J Immunol. 147:3229–3236.
1991.PubMed/NCBI
|
|
10
|
Yokoyama WM and Seaman WE: The Ly-49 and
NKR-P1 gene families encoding lectin-like receptors on natural
killer cells: The NK gene complex. Annu Rev Immunol. 11:613–635.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hao L, Klein J and Nei M: Heterogeneous
but conserved natural killer receptor gene complexes in four major
orders of mammals. Proc Natl Acad Sci USA. 103:3192–3197. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kane KP, Lavender KJ and Ma BJ: Ly-49
receptors and their functions. Crit Rev Immunol. 24:321–348. 2004.
View Article : Google Scholar
|
|
13
|
Carlyle JR, Mesci A, Ljutic B, Belanger S,
Tai LH, Rousselle E, Troke AD, Proteau MF and Makrigiannis AP:
Molecular and genetic basis for strain-dependent NK1.1
alloreactivity of mouse NK cells. J Immunol. 176:7511–7524. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Carlyle JR, Mesci A, Fine JH, Chen P,
Bélanger S, Tai LH and Makrigiannis AP: Evolution of the Ly49 and
Nkrp1 recognition systems. Semin Immunol. 20:321–330. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Plougastel B, Dubbelde C and Yokoyama WM:
Cloning of Clr, a new family of lectin-like genes localized between
mouse Nkrp1a and Cd69. Immunogenetics. 53:209–214. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rahim MM, Chen P, Mottashed AN, Mahmoud
AB, Thomas MJ, Zhu Q, Brooks CG, Kartsogiannis V, Gillespie MT,
Carlyle JR, et al: The mouse NKR-P1B:Clr-b recognition system is a
negative regulator of innate immune responses. Blood.
125:2217–2227. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Perez-Diez A, Joncker NT, Choi K, Chan WF,
Anderson CC, Lantz O and Matzinger P: CD4 cells can be more
efficient at tumor rejection than CD8 cells. Blood. 109:5346–5354.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Taieb J, Chaput N, Ménard C, Apetoh L,
Ullrich E, Bonmort M, Péquignot M, Casares N, Terme M, Flament C,
et al: A novel dendritic cell subset involved in tumor
immunosurveillance. Nat Med. 12:214–219. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chan CW, Crafton E, Fan HN, Flook J,
Yoshimura K, Skarica M, Brockstedt D, Dubensky TW, Stins MF, Lanier
LL, et al: Interferon-producing killer dendritic cells provide a
link between innate and adaptive immunity. Nat Med. 12:207–213.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Maroof A, Beattie L, Zubairi S, Svensson
M, Stager S and Kaye PM: Posttranscriptional regulation of II10
gene expression allows natural killer cells to express
immunoregulatory function. Immunity. 29:295–305. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Huarte E, Rynda-Apple A, Riccardi C,
Skyberg JA, Golden S, Rollins MF, Ramstead AG, Jackiw LO, Maddaloni
M and Pascual DW: Tolerogen-induced interferon-producing killer
dendritic cells (IKDCs) protect against EAE. J Autoimmun.
37:328–341. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Perona-Wright G, Mohrs K, Szaba FM, Kummer
LW, Madan R, Karp CL, Johnson LL, Smiley ST and Mohrs M: Systemic
but not local infections elicit immunosuppressive IL-10 production
by natural killer cells. Cell Host Microbe. 6:503–512. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Brooks DG, Trifilo MJ, Edelmann KH, Teyton
L, McGavern DB and Oldstone MB: Interleukin-10 determines viral
clearance or persistence in vivo. Nat Med. 12:1301–1309. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Terme M, Ullrich E, Aymeric L, Meinhardt
K, Coudert JD, Desbois M, Ghiringhelli F, Viaud S, Ryffel B, Yagita
H, et al: Cancer-induced immunosuppression: IL-18-elicited
immunoablative NK cells. Cancer Res. 72:2757–2767. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cook KD and Whitmire JK: The depletion of
NK cells prevents T cell exhaustion to efficiently control
disseminating virus infection. J Immunol. 190:641–649. 2013.
View Article : Google Scholar
|
|
26
|
Noval Rivas M, Hazzan M, Weatherly K,
Gaudray F, Salmon I and Braun MY: NK cell regulation of CD4 T
cell-mediated graft-versus-host disease. J Immunol. 184:6790–6798.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Smahel M, Síma P, Ludvíková V, Marinov I,
Pokorná D and Vonka V: Immunisation with modified HPV16 E7 genes
against mouse oncogenic TC-1 cell sublines with downregulated
expression of MHC class I molecules. Vaccine. 21:1125–1136. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lin KY, Guarnieri FG, Staveley-O'Carroll
KF, Levitsky HI, August JT, Pardoll DM and Wu TC: Treatment of
established tumors with a novel vaccine that enhances major
histocompatibility class II presentation of tumor antigen. Cancer
Res. 56:21–26. 1996.PubMed/NCBI
|
|
29
|
Neufert C, Becker C and Neurath MF: An
inducible mouse model of colon carcinogenesis for the analysis of
sporadic and inflammation-driven tumor progression. Nat Protoc.
2:1998–2004. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Richter J, Capková K, Hříbalová V,
Vannucci L, Danyi I, Malý M and Fišerová A: Collagen-induced
arthritis: Severity and immune response attenuation using
multivalent N-acetyl glucosamine. Clin Exp Immunol. 177:121–133.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Scalzo AA, Lyons PA, Fitzgerald NA, Forbes
CA and Shellam GR: The BALB. B6-Cmv1r mouse: A strain congenic for
Cmv1 and the NK gene complex. Immunogenetics. 41:148–151. 1995.
View Article : Google Scholar
|
|
32
|
Taherzadeh Z, VanBavel E, de Vos J,
Matlung HL, van Montfrans G, Brewster LM, Seghers L, Quax PH and
Bakker EN: Strain-dependent susceptibility for hypertension in mice
resides in the natural killer gene complex. Am J Physiol Heart Circ
Physiol. 298:H1273–H1282. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Brown MG, Scalzo AA, Stone LR, Clark PY,
Du Y, Palanca B and Yokoyama WM: Natural killer gene complex (Nkc)
allelic variability in inbred mice: Evidence for Nkc haplotypes.
Immunogenetics. 53:584–591. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Radulovic K, Manta C, Rossini V, Holzmann
K, Kestler HA, Wegenka UM, Nakayama T and Niess JH: CD69 regulates
type I IFN-induced tolerogenic signals to mucosal CD4 T cells that
attenuate their colitogenic potential. J Immunol. 188:2001–2013.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ljunggren HG: Cancer immunosurveillance:
NKG2D breaks cover. Immunity. 28:492–494. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wu J, Song Y, Bakker AB, Bauer S, Spies T,
Lanier LL and Phillips JH: An activating immunoreceptor complex
formed by NKG2D and DAP10. Science. 285:730–732. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Raulet DH: Roles of the NKG2D
immunoreceptor and its ligands. Nat Rev Immunol. 3:781–790. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cerwenka A, Bakker AB, McClanahan T,
Wagner J, Wu J, Phillips JH and Lanier LL: Retinoic acid early
inducible genes define a ligand family for the activating NKG2D
receptor in mice. Immunity. 12:721–727. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Diefenbach A, Jamieson AM, Liu SD, Shastri
N and Raulet DH: Ligands for the murine NKG2D receptor: Expression
by tumor cells and activation of NK cells and macrophages. Nat
Immunol. 1:119–126. 2000. View
Article : Google Scholar
|
|
40
|
Diefenbach A, Jensen ER, Jamieson AM and
Raulet DH: Rae1 and H60 ligands of the NKG2D receptor stimulate
tumour immunity. Nature. 413:165–171. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Végran F, Apetoh L and Ghiringhelli F: Th9
cells: A novel CD4 T-cell subset in the immune war against cancer.
Cancer Res. 75:475–479. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Reinis M, Símová J, Indrová M, Bieblová J,
Pribylová H, Moravcová S, Jandlová T and Bubeník J: Immunization
with MHC class I-negative but not -positive HPV16-associated tumour
cells inhibits growth of MHC class I-negative tumours. Int J Oncol.
30:1011–1017. 2007.PubMed/NCBI
|
|
43
|
Indrová M, Símová J, Bieblová J, Bubeník J
and Reinis M: NK1.1+ cells are important for the
development of protective immunity against MHC I-deficient,
HPV16-associated tumours. Oncol Rep. 25:281–288. 2011.
|
|
44
|
Wang D and DuBois RN: Immunosuppression
associated with chronic inflammation in the tumor microenvironment.
Carcinogenesis. 36:1085–1093. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Mikyšková R, Indrová M, Polláková V,
Bieblová J, Símová J and Reiniš M: Cyclophosphamide-induced
myeloid-derived suppressor cell population is immunosuppressive but
not identical to myeloid-derived suppressor cells induced by
growing TC-1 tumors. J Immunother. 35:374–384. 2012. View Article : Google Scholar
|
|
46
|
Guo Y, Wu Y, Zhao M, Kong XP and Liu Y:
Mutational analysis and an alternatively spliced product of B7
defines its CD28/CTLA4-binding site on immunoglobulin C-like
domain. J Exp Med. 181:1345–1355. 1995. View Article : Google Scholar : PubMed/NCBI
|
